Hikma Pharmaceuticals (LON:HIK) Share Price Passes Above 200 Day Moving Average – Here’s What Happened

Hikma Pharmaceuticals PLC (LON:HIK)’s share price crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 1,448.74 and traded as high as GBX 1,575. Hikma Pharmaceuticals shares last traded at GBX 1,557.81, with a volume of 24,302,965 shares trading hands.

Wall Street Analyst Weigh In

HIK has been the subject of a number of research reports. Jefferies Financial Group upped their price objective on shares of Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a GBX 195 price target on shares of Hikma Pharmaceuticals in a report on Monday, June 22nd. Berenberg Bank reaffirmed a “buy” rating and issued a GBX 1,800 price target on shares of Hikma Pharmaceuticals in a research report on Tuesday, April 28th. Finally, Citigroup reiterated a “buy” rating on shares of Hikma Pharmaceuticals in a research note on Thursday, July 16th. Six investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of GBX 1,687.

Hikma Pharmaceuticals Stock Up 1.9%

The business’s fifty day moving average price is GBX 1,505.78 and its two-hundred day moving average price is GBX 1,449.68. The company has a debt-to-equity ratio of 61.84, a quick ratio of 1.27 and a current ratio of 1.82. The firm has a market capitalization of £3.33 billion, a P/E ratio of 8.74, a PEG ratio of 2.38 and a beta of 0.65.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.